Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
about
Regulation of immune cell function and differentiation by the NKG2D receptorNatural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approachesNKG2D ligands as therapeutic targetsAdvantages and applications of CAR-expressing natural killer cellsNKG2D Ligands in Tumor Immunity: Two Sides of a CoinA review of the past, present, and future directions of neoplasiaComing of Age in the Life ofNeoplasia: Where We Have Been and Where We Are GoingThe structure of the atypical killer cell immunoglobulin-like receptor, KIR2DL4.An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit sheddingPerturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.New insights into the role of EMT in tumor immune escape.Interleukin 10 decreases MICA expression on melanoma cell surface.NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational studyOpportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseElevation of soluble major histocompatibility complex class I related chain A protein in malignant and infectious diseases in Chinese patientsTranscriptional regulation of ULBP1, a human ligand of the NKG2D receptor.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.NK cell-based immunotherapies in Pediatric Oncology.Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells.Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Soluble HLA-G: Are they clinically relevant?Immunotherapy of neuroblastoma: present, past and future.PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillanceEffective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.Interaction Between Polymorphisms of IFN-γ and MICA Correlated with Hepatocellular Carcinoma.Activation and self-tolerance of natural killer cells.Immunology and immunotherapy of neuroblastomaRegulation of ligands for the activating receptor NKG2D.DNA damage response and development of targeted cancer treatments.NK cell receptors and their ligands in leukemia.Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.NKG2D ligands in tumor immunity.
P2860
Q24635093-BE43CA8E-AB0B-40F4-8A32-ED92C1099C2DQ26825652-7A4848DA-8DE4-49DE-8783-B1B5EF059C3AQ27014888-2BEAB2A2-6F7A-4BA4-B843-C71150E0D50AQ28080875-B471F4B3-AA1E-45CB-9466-A1BAF22E95DAQ28083832-AE5E043F-7E1B-4E0E-9F23-8D836B3237E8Q28389391-1FFA1C3D-2926-4DD5-ABDD-361C8E22FDFCQ28389985-A033E572-D742-41AC-A9E4-B0B7E53C124DQ28395095-C2FCF28A-4666-491C-83A6-12CE5F395255Q30372604-7265C26D-273F-455E-A8D8-ADAB9CBCF6D2Q30489974-EB810C6E-4AA2-492A-8C97-B154EBF10178Q30547087-3457CC28-4926-4EEA-A3DB-63DECE9C8FEAQ33639723-3473AC12-DE01-41B8-B77A-FA6104FE583BQ33869781-CD857A8C-1102-4C55-917F-8BBB45A8A615Q34131549-9E51FBC7-1E7E-4921-A747-53F0030C6FD6Q34132372-B2C0A469-FCAE-40D6-9B2C-50584D3F7614Q34307792-A621A41E-EF27-42C0-8E21-8E94D0C4A230Q34488774-00FB1DA6-06F9-4CFF-8E10-3580AC6ED084Q34556241-88FCF5EB-0E7C-4FFE-84BD-5454AC64C5C0Q35283020-ABFFA43D-23C5-4C96-84AE-ED68DB16C1F1Q35600975-FA3C2E66-EDD5-4596-8846-69A7DB15D0E2Q35654544-142DE903-4CBE-4155-9170-7684894AC0ECQ35664913-0DAE0BDB-E9DD-4C83-AFEB-9F4BFF2838E5Q35799094-C179FE7A-2BFE-454F-95EA-A8F8A493F423Q35847668-0AC312AC-BA27-4B02-AAB1-3603E7B2705CQ36110266-7DAC3498-8324-41D9-9978-998E51A37342Q36114222-008DB29A-ABAC-4AF8-BF54-2E26D044592DQ36269694-76891011-DF54-446E-8C56-A321886AF86DQ36384011-1CDBAE28-32CC-48AF-902C-90D996F34189Q36453273-6E5D28C1-6FA3-43A3-AE62-59B13F6205E1Q36597354-0706F273-3E5A-4831-8258-08FAB09DFC2FQ36597374-5DA598A8-6604-4E17-89D6-F418DABA82C8Q36603556-C0C78AAB-3661-4218-B90B-802A5751FC2AQ36652183-9C454B67-3D46-4D3B-AA6C-4B5757E5B03CQ36856798-0E2D3223-8A77-4537-9079-5BA47E3DF03EQ36872056-68C7753B-8107-430A-9E8D-96348BF06722Q36939423-40D5ADF9-4AF3-49D7-B39F-A3D03E160210Q37018656-42927D68-6E87-4CAB-B751-FCB6884207A1Q37222064-3C754811-FFAB-42D6-8969-DB9C71043B92Q37242917-1C8661B8-21C3-44D4-B27B-51921112C665Q37287179-BB12DF28-F578-49E4-8D2D-A3CEBCDD2D56
P2860
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Downregulation and/or release ...... rategy of human neuroblastoma.
@en
type
label
Downregulation and/or release ...... rategy of human neuroblastoma.
@en
prefLabel
Downregulation and/or release ...... rategy of human neuroblastoma.
@en
P2093
P2860
P356
P1433
P1476
Downregulation and/or release ...... rategy of human neuroblastoma.
@en
P2093
Alexander Steinle
Claudio Gambini
Daniela Pende
Ignazia Prigione
Irma Airoldi
Isabella Levreri
Marta Camoriano
Soldano Ferrone
Vito Pistoia
P2860
P304
P356
10.1593/NEO.04316
P577
2004-09-01T00:00:00Z